S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   271.99 (+1.67%)
AAPL   111.46 (+1.25%)
MSFT   207.27 (+2.34%)
FB   254.01 (+2.36%)
GOOGL   1,456.30 (+1.83%)
AMZN   3,121.96 (+5.45%)
NVDA   504.19 (+0.70%)
TSLA   429.38 (-4.45%)
BABA   275.29 (+0.54%)
CGC   16.10 (+2.29%)
GE   6.23 (-1.89%)
MU   49.70 (+1.12%)
AMD   77.53 (-0.53%)
T   28.52 (-0.38%)
F   6.78 (-1.31%)
ACB   6.72 (+6.33%)
GILD   63.52 (-1.07%)
NFLX   490.77 (+0.70%)
DIS   127.20 (+1.43%)
BAC   23.92 (-2.25%)
BA   156.57 (+0.14%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   271.99 (+1.67%)
AAPL   111.46 (+1.25%)
MSFT   207.27 (+2.34%)
FB   254.01 (+2.36%)
GOOGL   1,456.30 (+1.83%)
AMZN   3,121.96 (+5.45%)
NVDA   504.19 (+0.70%)
TSLA   429.38 (-4.45%)
BABA   275.29 (+0.54%)
CGC   16.10 (+2.29%)
GE   6.23 (-1.89%)
MU   49.70 (+1.12%)
AMD   77.53 (-0.53%)
T   28.52 (-0.38%)
F   6.78 (-1.31%)
ACB   6.72 (+6.33%)
GILD   63.52 (-1.07%)
NFLX   490.77 (+0.70%)
DIS   127.20 (+1.43%)
BAC   23.92 (-2.25%)
BA   156.57 (+0.14%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   271.99 (+1.67%)
AAPL   111.46 (+1.25%)
MSFT   207.27 (+2.34%)
FB   254.01 (+2.36%)
GOOGL   1,456.30 (+1.83%)
AMZN   3,121.96 (+5.45%)
NVDA   504.19 (+0.70%)
TSLA   429.38 (-4.45%)
BABA   275.29 (+0.54%)
CGC   16.10 (+2.29%)
GE   6.23 (-1.89%)
MU   49.70 (+1.12%)
AMD   77.53 (-0.53%)
T   28.52 (-0.38%)
F   6.78 (-1.31%)
ACB   6.72 (+6.33%)
GILD   63.52 (-1.07%)
NFLX   490.77 (+0.70%)
DIS   127.20 (+1.43%)
BAC   23.92 (-2.25%)
BA   156.57 (+0.14%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   271.99 (+1.67%)
AAPL   111.46 (+1.25%)
MSFT   207.27 (+2.34%)
FB   254.01 (+2.36%)
GOOGL   1,456.30 (+1.83%)
AMZN   3,121.96 (+5.45%)
NVDA   504.19 (+0.70%)
TSLA   429.38 (-4.45%)
BABA   275.29 (+0.54%)
CGC   16.10 (+2.29%)
GE   6.23 (-1.89%)
MU   49.70 (+1.12%)
AMD   77.53 (-0.53%)
T   28.52 (-0.38%)
F   6.78 (-1.31%)
ACB   6.72 (+6.33%)
GILD   63.52 (-1.07%)
NFLX   490.77 (+0.70%)
DIS   127.20 (+1.43%)
BAC   23.92 (-2.25%)
BA   156.57 (+0.14%)
Log in
NYSE:PFE

Pfizer Stock Forecast, Price & News

$36.12
+0.10 (+0.28 %)
(As of 09/22/2020 04:32 PM ET)
Add
Compare
Today's Range
$35.74
Now: $36.12
$36.33
50-Day Range
$35.65
MA: $37.56
$38.88
52-Week Range
$27.88
Now: $36.12
$40.97
Volume1.11 million shs
Average Volume29.35 million shs
Market Capitalization$200.71 billion
P/E Ratio14.33
Dividend Yield4.15%
Beta0.67
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands. The company also provides consumer healthcare products that comprise over-the-counter medicines, including dietary supplement products under the Centrum, Caltrate, and Emergen-C names; pain management products under the Advil and ThermaCare names; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H names; and respiratory and personal care products under the Robitussin, Advil Cold & Sinus, and ChapStick names. In addition, it offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit, Ixifi Infliximab BS names. Further, the company is also involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Merck KGaA; licensing agreement with BionTech AG; and collaboration agreements with Merck & Co., Inc. and Eli Lilly & Company, as well as with Merck KGaA and Nektar Therapeutics to develop a therapy for treating pancreatic cancer. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More
Pfizer logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.9Dividend Strength: 3.3Insider Behavior: 4.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.73 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP71708110
Phone212-733-2323

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$51.75 billion
Cash Flow$4.11 per share
Book Value$11.46 per share

Profitability

Net Income$16.27 billion

Miscellaneous

Employees88,300
Outstanding Shares5,556,880,000
Market Cap$200.71 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$36.12
+0.10 (+0.28 %)
(As of 09/22/2020 04:32 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pfizer (NYSE:PFE) Frequently Asked Questions

How has Pfizer's stock price been impacted by Coronavirus (COVID-19)?

Pfizer's stock was trading at $32.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PFE shares have increased by 12.3% and is now trading at $36.12.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Pfizer?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Pfizer
.

When is Pfizer's next earnings date?

Pfizer is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Pfizer
.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) issued its quarterly earnings data on Tuesday, July, 28th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.64 by $0.14. The biopharmaceutical company had revenue of $11.80 billion for the quarter, compared to analyst estimates of $11.55 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The business's quarterly revenue was down 11.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.80 EPS.
View Pfizer's earnings history
.

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer announced a quarterly dividend on Thursday, June 25th. Stockholders of record on Friday, July 31st will be given a dividend of $0.38 per share on Tuesday, September 1st. This represents a $1.52 annualized dividend and a dividend yield of 4.21%. The ex-dividend date is Thursday, July 30th.
View Pfizer's dividend history
.

How will Pfizer's stock buyback program work?

Pfizer announced that its Board of Directors has authorized a share buyback plan on Friday, December 14th 2018, which authorizes the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 3.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's board believes its shares are undervalued.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY20 earnings guidance on Tuesday, July, 28th. The company provided earnings per share guidance of $2.85-2.95 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.72. The company issued revenue guidance of $48.6-50.6 billion, compared to the consensus revenue estimate of $48.11 billion.

What price target have analysts set for PFE?

11 analysts have issued 12-month price objectives for Pfizer's stock. Their forecasts range from $24.00 to $53.00. On average, they expect Pfizer's share price to reach $39.57 in the next year. This suggests a possible upside of 9.6% from the stock's current price.
View analysts' price targets for Pfizer
.

Has Pfizer been receiving favorable news coverage?

News articles about PFE stock have been trending negative this week, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pfizer earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Pfizer
.

Are investors shorting Pfizer?

Pfizer saw a increase in short interest in July. As of July 31st, there was short interest totaling 53,490,000 shares, an increase of 12.7% from the July 15th total of 47,470,000 shares. Based on an average trading volume of 31,180,000 shares, the days-to-cover ratio is presently 1.7 days.
View Pfizer's Short Interest
.

Who are some of Pfizer's key competitors?

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS), Merck & Co., Inc. (MRK), Exxon Mobil (XOM) and JPMorgan Chase & Co. (JPM).

Who are Pfizer's key executives?

Pfizer's management team includes the following people:
  • Mr. Ian C. Read, Exec. Chairman (Age 65)
  • Mr. Albert Bourla D.V.M., DVM, Ph.D., CEO & Director (Age 57)
  • Mr. Frank A. D'Amelio, CFO & EVP of Global Supply & Bus. Operations (Age 61)
  • Dr. Mikael Dolsten, Chief Scientific Officer & Pres of Worldwide Research, Devel. and Medical (Age 60)
  • Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 54)

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Who are Pfizer's major shareholders?

Pfizer's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.22%), BlackRock Inc. (7.69%), Bank of New York Mellon Corp (1.03%), Charles Schwab Investment Management Inc. (0.72%), Goldman Sachs Group Inc. (0.56%) and Sanders Capital LLC (0.51%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Jennifer B Damico, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Ronald E Blaylock and Scott Gottlieb.
View institutional ownership trends for Pfizer
.

Which institutional investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including TD Asset Management Inc., Epoch Investment Partners Inc., Toronto Dominion Bank, Vanguard Group Inc., Marshall Wace North America L.P., Federated Hermes Inc., Fisher Asset Management LLC, and Bank of Nova Scotia. Company insiders that have sold Pfizer company stock in the last year include Douglas M Lankler, and Jennifer B Damico.
View insider buying and selling activity for Pfizer
.

Which institutional investors are buying Pfizer stock?

PFE stock was purchased by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Two Sigma Advisers LP, BlackRock Inc., Healthcare of Ontario Pension Plan Trust Fund, First Trust Advisors LP, FIL Ltd, Handelsbanken Fonder AB, and Sanders Capital LLC. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc, Ronald E Blaylock, and Scott Gottlieb.
View insider buying and selling activity for Pfizer
.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $36.12.

How big of a company is Pfizer?

Pfizer has a market capitalization of $200.71 billion and generates $51.75 billion in revenue each year. The biopharmaceutical company earns $16.27 billion in net income (profit) each year or $2.95 on an earnings per share basis. Pfizer employs 88,300 workers across the globe.

What is Pfizer's official website?

The official website for Pfizer is www.pfizer.com.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.